Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Insulin lispro].

A Matsuda1

  • 1Utsunomiya Chyuo Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Insulin lispro, a rapid-acting insulin analog, demonstrated faster absorption and a quicker onset of action compared to regular human insulin. Clinical studies confirmed its efficacy in improving postprandial glucose control in diabetic patients without adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCS-like Bogoliubov quasiparticles in high-T(c) superconductors observed by angle-resolved photoemission spectroscopy.

Physical review letters·2003
Same author

Low energy excitation and scaling in Bi(2)Sr(2)Ca(n-1)Cu(n)O(2n+4) (n=1-3): angle-resolved photoemission spectroscopy.

Physical review letters·2002
Same author

Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.

Annals of hematology·2002
Same author

[Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2002
Same author

The molecular basis for the alternative stable phenotype in a behavioral mutant of Paramecium tetraurelia.

Genes & genetic systems·2002
Same author

Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2001
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Pharmacology and Endocrinology
  • Clinical Diabetes Management

Background:

  • Insulin therapy is central to diabetes mellitus management.
  • Rapid-acting insulin analogs aim to mimic physiological insulin secretion more closely.
  • Clinical validation of insulin lispro in Japan was necessary to confirm its therapeutic profile.

Purpose of the Study:

  • To summarize clinical study results for insulin lispro in Japan.
  • To evaluate the pharmacodynamics, pharmacokinetics, efficacy, and safety of insulin lispro.
  • To compare insulin lispro with human regular insulin.

Main Methods:

  • Single subcutaneous injection studies in healthy volunteers.
  • Long-term, multicenter, randomized, comparative, parallel, open-label study in type 1 and type 2 diabetic patients.

Related Experiment Videos

  • Multiple injection method assessed over 12 and 24 weeks.

    • Main Results:

    • Insulin lispro showed more rapid absorption and elimination compared to human regular insulin.
    • It exhibited an earlier onset and more potent hypoglycemic action.
    • Significant improvement in 2-hour postprandial blood glucose levels was observed.
    • HbA1c levels remained stable, and no adverse effects were reported over 48 weeks.

    Conclusions:

    • Insulin lispro is a safe and effective short-acting insulin for diabetes treatment.
    • Its pharmacokinetic and pharmacodynamic profile supports its use in managing postprandial hyperglycemia.
    • Clinical studies in Japan confirm the therapeutic utility of insulin lispro.